Treatment-Altered VEGF-Associated Network in GBM BVZ-Responsive Subtypes: Bioinformatics Case Studies
Authors:
Open Access
- 3 May 2023
- journal article
- Published by Gavin Publishers in Annals of Case Reports
- Vol. 8 (2)
Abstract
Glioblastoma multiforme (GBM) is the deadliest brain tumor with a median lifespan of approximately 15 months after diagnosis[1]. As GBM is a heterogenKeywords
This publication has 25 references indexed in Scilit:
- Effects of Eph/ephrin signalling and human Alzheimer's disease-associated EphA1 on Drosophila behaviour and neurophysiologyNeurobiology of Disease, 2022
- Diffuse midline glioma: review of epigeneticsJournal of Neuro-Oncology, 2020
- MicroRNAs as biomarkers for human glioblastoma: progress and potentialActa Pharmacologica Sinica, 2018
- Wnt signaling positively regulates endothelial cell fate specification in the Fli1a-positive progenitor population via Lef1Developmental Biology, 2017
- The role of bevacizumab in the treatment of glioblastomaJournal of Neuro-Oncology, 2017
- Regulatory networks between neurotrophins and miRNAs in brain diseases and cancersActa Pharmacologica Sinica, 2014
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Mechanisms of angiogenesis and arteriogenesisNature Medicine, 2000
- Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic AngiogenesisCell, 1996
- Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression CloningCell, 1996